Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to ...

Jan. 22, 2015 /PRNewswire/ -- Nevro Corp. (NYSE ... of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system. According to the approvable letter, approval ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS ... Senza®, Senza II®, Senza Omnia™, and HFX iQ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.

Nevro's comprehensive HFX™ spinal cord stimulation (SCS ... Senza®, Senza II ®, Senza Omnia™, and HFX iQ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy.

Globus Medical plans to buy spinal cord stimulation company Nevro for about $250 million, the companies announced on Thursday. Globus will pay $5.85 per share in an all-cash purchase, a 27% ...